Aimmune Therapeutics, which is developing an oral immunotherapy designed to lessen the effects of peanut allergies, filed on Monday with the SEC to raise up to $115 million in an initial public offering.
The company notes that it may face competition DBV Technologies (DBVT), which is developing an immunotherapy patch for food allergies, including peanut. The French biotech listed its shares in the US in October 2014 and has since traded up about 40%, giving it a market cap of over $1 billion. It recently filed to raise $150 million in a follow-on offering.
The Brisbane, CA-based company, which was founded in 2011 as Allergen Research, plans to list on the NASDAQ under the symbol AIMT. Aimmune Therapeutics initially filed confidentially on June 4, 2015. BofA Merrill Lynch, Credit Suisse and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
